Dr. Mowery is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5230 Centre Ave
Pittsburgh, PA 15232Phone+1 412-623-7088Fax+1 412-623-6725
Summary
- Yvonne M. Mowery, MD, PhD, DABR is a physician scientist and an Associate Professor of Radiation Oncology at University of Pittsburgh/UPMC Hillman Cancer Center. She is a board-certified radiation oncologist, specializing in treating head and neck cancer, base of skull tumors, and skin cancer. She received her MD and PhD in Pathology at Duke University in 2012, followed by completing an Internal Medicine internship and Radiation Oncology residency at Duke University in 2017. She was the Butler Harris Assistant Professor of Radiation Oncology at Duke University through May 2023 prior to moving to UPMC Hillman Cancer Center. Her laboratory focuses on studying head and neck cancer pathogenesis and mechanisms of overcoming radiation and immunotherapy resistance in head and neck squamous cell carcinoma (HNSCC), with a particular interest in DNA damage response pathways. Yvonne previously served as the Associate Center Director for Radioimmunotherapy for the Duke Cancer Institute Center of Cancer Immunotherapy, and she was awarded a 2021 American Society for Clinical Investigation Young Physician-Scientist Award. She is the PI of an investigator-initiated phase I trial (NCT04576091) evaluating the ATR inhibitor BAY 1895344 with pembrolizumab and stereotactic body radiation therapy for recurrent HNSCC. Her research support includes a K08 Career Development Award from the National Institute of Dental and Craniofacial Research and a Damon Runyon Clinical Investigator Award.
Education & Training
- Duke University HospitalResidency, Radiation Oncology, 2013 - 2017
- Duke University HospitalInternship, Internal Medicine, 2012 - 2013
- Duke University School of MedicineClass of 2012
Certifications & Licensure
- NC State Medical License 2012 - 2025
- PA State Medical License 2023 - 2024
- VA State Medical License 2020 - 2024
- American Board of Radiology Radiation Oncology
Clinical Trials
- PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based Study Start of enrollment: 2018 Jun 19
- Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx Start of enrollment: 2021 Apr 12
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Start of enrollment: 2022 Jul 06
- Join now to see all
Publications & Presentations
PubMed
- International Expert-Based Consensus Definition, Classification Criteria, and Minimum Data Elements for Osteoradionecrosis of the Jaw: An Inter-Disciplinary Modified D...Amy C Moreno, Erin E Watson, Laia Humbert-Vidan, Douglas E Peterson, Lisanne V van Dijk
International Journal of Radiation Oncology, Biology, Physics. 2025-01-16 - 5 citationsLong-term risk of carotid stenosis and cerebrovascular disease after radiation therapy for head and neck cancer.David J Carpenter, Pranalee Patel, Donna Niedzwiecki, Mairead Dillon, Alexander K Diaz
Cancer. 2025-01-01 - Clinical commissioning and introduction of an in-house artificial intelligence (AI) platform for automated head and neck intensity modulated radiation therapy (IMRT) t...Xinyi Li, Yang Sheng, Qingrong Jackie Wu, Yaorong Ge, David M Brizel
Journal of Applied Clinical Medical Physics. 2025-01-01
Press Mentions
- Adding Pembrolizumab Ups Survival in Stage III Undifferentiated SarcomaNovember 22nd, 2024
- Pembrolizumab, an Immunotherapy Medication, Improves Outcomes for Patients with Soft Tissue SarcomaNovember 14th, 2024
- HMN 2024: Immunotherapy Drug Pembrolizumab Improves Outcomes for Patients with Soft Tissue SarcomaNovember 13th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: